Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 24, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 24, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/17/17 - "Dosing Preparation of Dabigatran Etexilate Or a Salt Thereof and a Preparation Method Thereof" in Patent Application Approval Process (USPTO...
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors SHENG, Xiaoxia; TANG, Yong, filed on October 8, 2015, was made available online on March 2, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to SoliPharma LLC. Dabigatran etexila
3/17/17 - AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX ombitasvir/paritaprevir/ritonavir tablets + EXVIERA dasabuvir...
By a News Reporter-Staff News Editor at Drug Week AbbVie, a global biopharmaceutical company, announced that the European Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion for a shorter, eight-week treatment of VIEKIRAX + EXVIERA as an option for previously untreated adult patients
3/17/17 - AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE
AC IMMUNE reports Full year 2016 financial results and R&D update. Strong cash position of CHF 152.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Successful IPO on NASDAQ raised net proceeds of CHF 69.4 million Important data on crenezumab supporting 60 mg/kg dose in partner Genentech's CREAD P
3/17/17 - Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's Disease
By a News Reporter-Staff News Editor at Drug Week- Accera, Inc., a leading CNS therapeutics company, announced results of the AC-1204 Phase 3 study for the treatment of mild-to-moderate Alzheimer's disease. Charles Stacey, MD, the company's President and Chief Executive Officer commented, "The trial result is disappointing for us and the millions
3/17/17 - Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference [National Iraqi News Agency (Iraq)]
-Agile Therapeutics, Inc., a womens healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical trial for its lead product candidate, Twirla,, also known as AG200-15. The poster, titled The SECURE Study, a Real-World Trial of a Low-Dose Contraceptive Patch: Addressing the Changing U.S. Population, will be presented
3/17/17 - Akari Therapeutics Announces R&D Day on April 24, 2017
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. Interim results from the ongoing phase 2 trial in paroxysmal nocturnal hemoglobinuria will be presented by Dr Anita Hill, the lead investigator in the study. Dr Hill is a
3/17/17 - Astex bags milestone after Novartis cancer drug approved [Syrian Arab News Agency]
Astex Pharmaceuticals has pocketed a milestone payment from Novartis after the cancer drug the companies worked on together a decade ago secured FDA approval. The milestone was triggered when FDA signed off on the use of Kisqali as a first-line treatment for HR-positive, HER2-negative advanced breast cancer. That led to the publication of a paper o
3/17/17 - AstraZeneca Fires Back at Tesaro in Ovarian Cancer [Syrian Arab News Agency]
Following news that AstraZeneca`s PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc.. AstraZeneca`s Lynparza was the first PARP inhibitor to win FDA approval for use in
3/17/17 - AstraZeneca: FDA Issues Complete Response Letter For ZS-9
LONDON- AstraZeneca announced the US FDA has issued a Complete Response Letter regarding the New Drug Application for ZS-9. The CRL followed an inspection by the FDA of the ZS-9 manufacturing facility. Sodium zirconium cyclosilicate is being developed for the treatment of hyperkalaemia by ZS Pharma, a subsidiary of AstraZeneca.
3/17/17 - Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)
Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced that interim Phase 1 trial results from autologous, targeted Epstein-Barr Virus Specific Cytotoxic T Lymphocytes, or the autologous...
3/17/17 - AveXis`s AVXS-101 Phase I Trial Results Likely To Indicate Future Success [Sport360]
AveXis Inc is developing AVXS-101 for treatment of the genetic disease spinal muscular atrophy type 1. FDA has granted AVXS-101 orphan drug designation, breakthrough therapy designation, and fast track designation. The phase I trial was acknowledged by the FDA and was set as a single-arm study involving 20 patients and will use the natural history
3/17/17 - Breckenridge Pharmaceutical, Inc. Announces Launch of Desvenlafaxine XR Tablets generic for Pristiq
By a News Reporter-Staff News Editor at Drug Week- Breckenridge Pharmaceutical, Inc. announced the launch of desvenlafaxine succinate extended-release tablets 50 mg and 100 mg, a generic version of Pristiq by Pfizer Inc. The ANDA was filed as a Paragraph IV on the first-to-file date and will share 180- day exclusivity with other ANDA first fil
3/17/17 - Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation
In this U.S. Medicare database analysis, Eliquis was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin. PRINCETON, N.J.& NEW YORK Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Medicare database compa
3/17/17 - Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants...
Bristol-Myers Squibb Company and Pfizer Inc. today announced findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin. In the analysis, title
3/17/17 - China Biopharmaceutical and Pharmaceutical Regulatory Framework Reforms [Sudan Tribune]
The China Food and Drug Administration has noted a number of reforms to biopharmaceutical and pharmaceutical policy frameworks, aiming to encourage development, approval, and manufacture of required therapies. Shanghai- based legal experts Katherine Wang and Xiaoyi Liu of Ropes& Gray explain key elements of these new regulations and implications on
3/17/17 - CTD HOLDINGS INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
We filed a Type II Drug Master File with the FDA in 2014 for our lead drug candidate, Trappsol Cyclo? as a treatment for Neimann-Pick Type C disease, a rare and fatal cholesterol metabolism disease found primarily in children and young adults. In 2016, we filed an Investigational New Drug application with the FDA, which describes our Phase I c
3/17/17 - FDA Approves Merck`s Keytruda for Adult and Pediatric Patients With Classical Hodgkin Lymphoma [Sudan Tribune]
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, the companys anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma, or who have relapsed after three or more prior lines of therapy. Under the FDAs acce
3/17/17 - FDA Approves Novartis Kisqali As Metastatic Breast Cancer Treatment [Sport360]
Reports by the American Cancer Society reveal approximately 40 percent of U.S. women battling breast tumors are affected by metastatic breast cancer. The U.S. Food and Drug Administration confirmed the approval of Kisqali, which belongs to a class of pharmaceuticals called kinase inhibitors, on March 13. According to Novartis, a month`s supply of K
3/17/17 - Findings on Biopharmaceuticals Reported by Investigators at University of Bath (Biopharmaceutical aspects and implications of excipient variability...
Findings on Biopharmaceuticals Reported by Investigators at University of Bath. According to news reporting from Bath, United Kingdom, by NewsRx journalists, research stated, "Implementation of Quality by Design approaches in pharmaceutical industry requires a sound understanding of the parameters triggering final product variability.
3/17/17 - Findings on Myeloid Cells Described by Researchers at Takeda Pharmaceutical Company (Macrophage Migration Inhibitory Factor as an Emerging Drug...
Findings on Myeloid Cells Described by Researchers at Takeda Pharmaceutical Company. Our news editors obtained a quote from the research from Takeda Pharmaceutical Company, "Recently, by applying chemical biology approach with an ARE activator, BTZO-1, we found macrophage migration inhibitory factor as a new regulator of antioxidant response elemen
3/17/17 - Gainers & Losers Of Mar.16: MCRB, PLSE, OCUL, PTCT, TROV...
News: The Company plans to initiate a new phase II study of SER-109 in patients with multiply recurrent Clostridium Difficile infection that, as agreed to by the FDA, may qualify as a pivotal study. Anticipated event: The Company will release its financial results for the fourth quarter and full year ended December 31, 2016, on Thursday, March 23,
3/17/17 - Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
Galena Biopharma, Inc., a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced the final analysis from the Company s GALE-301 investigator-sponsored Phase 1/ 2 a clinical trial. Larry Maxwell at the Annual Meeting on Women s Cancer 2017 hosted by the Society of Gynecolog
3/17/17 - Generic Drugs to Slow Growth of Antifungal Market [Daily News Egypt]
-New proprietary research by BCC Research predicts that new and innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs. "BCC Research predicts that region and North America to account for 24.9% and 36.9
3/17/17 - Global Tele-Health Monitoring Market Size, Share, Trends, Growth, Regional Outlook and Forecast 2017 - Acute Market Reports
AcuteMarketReports.com has Published New Research Report Title "Tele-Health Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2011 to 2017" Market Research report to their Database. Acute Market Reports announces that it has a new study on Tele-Health Monitoring Market Shares and Forecasts, Worldwide, 2011-2017. The 2011 study has 44
3/17/17 - Global Tele-Health Monitoring Market Size, Share, Trends, Growth, Regional Outlook and Forecast 2017 Acute Market Reports
"Acute Market Reports" AcuteMarketReports.com has Published New Research Report Title "Tele-Health Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2011 to 2017" Market Research report to their Database. Acute Market Reports announces that it has a new study on Tele-Health Monitoring Market Shares and Forecasts, Worldwide, 2011-2017
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415